Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Variations in dose and dose intensity of adjuvant CMF chemotherapy for breast cancer throughout the UK
Autore:
Brown, RSD; Burcombe, RJ; Osborne, ME; Gaze, MN;
Indirizzi:
Middlesex Hosp, Meyerstein Inst Oncol, London W1N 8AA, England Middlesex Hosp London England W1N 8AA nst Oncol, London W1N 8AA, England Mt Vernon Hosp, Northwood HA6 2RN, Middx, England Mt Vernon Hosp Northwood Middx England HA6 2RN od HA6 2RN, Middx, England
Titolo Testata:
CLINICAL ONCOLOGY
fascicolo: 5, volume: 12, anno: 2000,
pagine: 315 - 323
SICI:
0936-6555(2000)12:5<315:VIDADI>2.0.ZU;2-F
Fonte:
ISI
Lingua:
ENG
Soggetto:
STAGE-II; THERAPY; CARCINOMA; SCHEDULE; REGIMENS;
Keywords:
adjuvant chemotherapy; CMF; dose intensity; survey; UK;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
25
Recensione:
Indirizzi per estratti:
Indirizzo: Gaze, MN Middlesex Hosp, Meyerstein Inst Oncol, Mortimer St, London W1N 8AA, England Middlesex Hosp Mortimer St London England W1N 8AA N 8AA, England
Citazione:
R.S.D. Brown et al., "Variations in dose and dose intensity of adjuvant CMF chemotherapy for breast cancer throughout the UK", CL ONCOL-UK, 12(5), 2000, pp. 315-323

Abstract

Cyclophosphamide, methotrexate and 5-fluorouracil (CMF) is a commonly prescribed regimen for the adjuvant treatment of early breast cancer in the UK and in other countries with a high incidence of breast carcinoma. A number of variations in dose and scheduling of these drugs have been reported in the literature, with all of these being recognized under the generic term 'CMF'. To investigate the extent of differences in CMF regimens used for the adjuvant treatment of early breast cancer we sent a postal questionnaire toall consultant medical and clinical oncologists in the UK seeking details of their practice. CMF drug doses were then converted into dose intensity parameters for comparison. The results showed a wide variation in the numberof CMF schedules (n = 36) and CMF dose intensities (n = 33) used. The potential consequences of such variation and the evidence for and against dose intensity as an important parameter in the adjuvant treatment of early breast cancer are discussed.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/09/20 alle ore 08:21:18